Literature DB >> 2150672

Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.

R W Carlson1, J H Doroshow, O O Odujinrin, M S Flam, M Malec, K R Lamborn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2150672     DOI： 10.1007/bf00198597

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  4 in total

Review 1.  Preclinical studies with trimetrexate: a review of conclusions and unanswered questions.

Authors:  R C Jackson; W R Leopold; K L Hamelehle; D W Fry
Journal:  Semin Oncol       Date:  1988-04       Impact factor: 4.929

2.  Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists.

Authors:  J A Stewart
Journal:  Semin Oncol       Date:  1988-04       Impact factor: 4.929

3.  Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone.

Authors:  B Lathan; D D Von Hoff; E Elslager
Journal:  Cancer Treat Rep       Date:  1984-05

4.  Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro.

Authors:  B A Kamen; B Eibl; A Cashmore; J Bertino
Journal:  Biochem Pharmacol       Date:  1984-05-15       Impact factor: 5.858
  4 in total
  4 in total

Review 1.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.

Authors:  L Rosenberg
Journal:  Int J Pancreatol       Date:  1997-10

Review 3.  Pancreatic cancer: a review of emerging therapies.

Authors:  L Rosenberg
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

Review 4.  Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer.

Authors:  Chitta Ranjan Patra; Resham Bhattacharya; Debabrata Mukhopadhyay; Priyabrata Mukherjee
Journal:  Adv Drug Deliv Rev       Date:  2009-11-13       Impact factor: 15.470
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.